Scarica l'app Stockscreener
1.09
6.03%
-0.07
Dopo l'orario di chiusura:
1.14
0.05
+4.59%
Precedente Chiudi:
$1.16
Aprire:
$1.15
Volume 24 ore:
726.88K
Relative Volume:
1.35
Capitalizzazione di mercato:
$57.19M
Reddito:
$21.05M
Utile/perdita netta:
$-89.22M
Rapporto P/E:
-0.6089
EPS:
-1.79
Flusso di cassa netto:
$-64.50M
1 W Prestazione:
-43.81%
1M Prestazione:
-44.67%
6M Prestazione:
-19.85%
1 anno Prestazione:
-81.65%
Intervallo 1D:
$1.07
$1.16
Intervallo di 1 settimana:
$1.07
$1.48
Portata 52W:
$1.02
$6.04
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Nome
Tscan Therapeutics Inc
Settore
Industria
Telefono
857-399-9500
Indirizzo
830 WINTER STREET, WALTHAM
Confronta TCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.09 | 65.83M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-16 | Iniziato | BTIG Research | Buy |
| 2024-05-13 | Iniziato | Needham | Buy |
| 2023-06-22 | Iniziato | Wedbush | Outperform |
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
Should you wait for a breakout in TScan Therapeutics Inc.July 2025 Technicals & Safe Entry Trade Reports - newser.com
What technical models suggest about TScan Therapeutics Inc.’s comeback - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fearsAnalyst Downgrade & Safe Capital Growth Plans - newser.com
Trend analysis for TScan Therapeutics Inc. this weekGap Down & Weekly Market Pulse Updates - newser.com
FY2025 EPS Forecast for TScan Therapeutics Raised by Analyst - Defense World
Applying chart zones and confluence areas to TScan Therapeutics Inc.Weekly Trade Analysis & Low Volatility Stock Recommendations - newser.com
Applying sector rotation models to TScan Therapeutics Inc.Weekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
How TScan Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - fcp.pa.gov.br
Reversal indicators forming on TScan Therapeutics Inc. stockJuly 2025 Selloffs & Smart Investment Allocation Insights - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Is TScan Therapeutics Inc. stock attractive for ETFsCPI Data & AI Driven Price Forecasts - fcp.pa.gov.br
Using data filters to optimize entry into TScan Therapeutics Inc.2025 Top Decliners & Consistent Return Investment Signals - newser.com
Can TScan Therapeutics Inc. stock maintain growth trajectoryPrice Action & Advanced Swing Trade Entry Plans - newser.com
Growth Value: Will TScan Therapeutics Inc. stock benefit from green energy trendsEarnings Recap Summary & Detailed Earnings Play Strategies - fcp.pa.gov.br
Technical signs of recovery in TScan Therapeutics Inc.GDP Growth & Daily Entry Point Trade Alerts - newser.com
Can swing trading help recover from TScan Therapeutics Inc. lossesEarnings Miss & Fast Gain Stock Trading Tips - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economy2025 Top Gainers & Technical Pattern Alert System - newser.com
TScan Therapeutics (NASDAQ:TCRX) Price Target Cut to $6.00 by Analysts at Needham & Company LLC - Defense World
TScan Therapeutics (TCRX) Projected to Post Earnings on Tuesday - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Price Target Lowered to $6.00 at Needham & Company LLC - MarketBeat
The time has not yet come to remove your chips from the table: Tscan Therapeutics Inc (TCRX) - setenews.com
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Barclays Reaffirms Their Buy Rating on TScan Therapeutics (TCRX) - The Globe and Mail
Best data tools to analyze TScan Therapeutics Inc. stockWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsCPI Data & Accurate Entry and Exit Point Alerts - newser.com
TScan Therapeutics Shares Fall After BTIG Research Downgrade - MarketScreener
Biotech firm TScan slashes jobs, extends cash runway amid strategic realignment - The Business Journals
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays By Investing.com - Investing.com Australia
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays - Investing.com India
BTIG Research Downgrades TScan Therapeutics to Neutral From Buy - MarketScreener
Needham Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq
TScan Therapeutics (TCRX) Analyst Update: Needham Lowers Price T - GuruFocus
TScan to focus on heme program, cuts workforce by 30% amid FDA progress - Investing.com Nigeria
Is TScan Therapeutics Inc. stock gaining market shareVolume Spike & Growth Oriented Trade Recommendations - fcp.pa.gov.br
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com - Investing.com Australia
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com
TScan Therapeutics Shifts Focus to Hematologic Malignancies - MSN
TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies - Quiver Quantitative
Tscan Therapeutics Inc Azioni (TCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.44%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):